). This offers precious information for the identification of bioactive molecular structures before their physical isolation, a process we define here as biodereplication and illustrate through the following examples. We would like to underline that if we have here incorporated ChEMBL datasets relevant to our current drug discovery objectives (i.e. anti-trypanosomatids), there are basically no limits to the incorporation of other bioactivity datasets comprised of chemical structure and their evaluated bioactivity on any given target -provided that these are shared publicly. This opens exciting possibilities as it becomes possible to detect spectrally related analogs of compounds previously bio-assayed by others, hence opening the possibility to fish potential bioactive compounds from complex extracts library without even realizing the initial screening campaigns nor the bioguided fractionation process.